Prepare for your next biopharma partnering deal with resources from biotech partnering consultant, Linda Pullan, PhD:

 

Non-IO in an IO World
Linda M. Pullan, Ph.D., Pullan Consulting 
Jeff Bockman, Ph.D., Defined Health
Peter Sandor, MD, MBA, Astellas
Axel Hoos, MD, Ph.D., GSK
Eric Haura, MD, H. Lee Moffitt Cancer Center

The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly "hot" area for pharmaceutical and biotech deal making.  With checkpoint antibodies seen as backbones for combination therapy in cancer, many in Oncology are asking... "What's the Role of Non-IO in an IO World?"

 WP-Non-IO-sm3.jpg

The Nuts & Bolts of Biopharma Due Diligence
Linda M. Pullan, Ph.D., Pullan Consulting 
James A. McCarthy, CLP, MBA, CorpDev Ventures
Natalie Mirutenko, Ph.D., Takeda
David L. Snitman, Ph.D., Array BioPharma
Paul Gattari, JD, McDonnell Boehnen Hulbert & Berghoff
Ann-Marie Costelloe, AFBPS, Somerville Partners
William Gangi, MS, MBA, Shire

Due diligence and finance experts from global pharmaceutical companies join legal advisors and consultants to share their expertise in a lively discussion on the issues that arise during due diligence.

 WP-Nuts&Bolts-sm3-1.jpg

What's Hot & What's Not in Immuno-Oncology Licensing, Parts 1 and 2
Linda M. Pullan, Ph.D., Pullan Consulting 
Jeff Bockman, Ph.D., Defined Health
Axel Hoos, MD, Ph.D., GSK
Ferran Prat, Ph.D., MD Anderson
Nathan Sanburn, MS, Lilly

The panelists discussed why immuno-oncology is so hot,  if it is too late to get into PD1 and other checkpoint inhibitors, how they judge immuno-oncology combinations, if CAR T can go into solid tumors, the impact of business models on cell therapy, winning strategies for deals in immuno-oncology licensing, cell recruitment, innate immunity, licensing criteria, biomarkers, deal terms, and more.

 WP-Immuno-Oncology-sm.jpg

What's Hot & What's Not in Oncology Licensing
Linda M. Pullan, Ph.D., Pullan Consulting 
Jeff Bockman, Ph.D., Defined Health
Paul Juniewicz, Ph.D., Sanofi
Ferran Prat, Ph.D., MD Anderson

The panelists discussed theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more.

WP-Oncology.jpg

Getting Ready for a Biopharma Partnering Deal
Linda M. Pullan, Ph.D., Pullan Consulting 

In order to thrive, biotechnology firms must successfully license their discoveries or, as is increasingly more common these days, partner with large pharmaceutical firms to develop their product. The right time to seek a partnering or licensing agreement and who to seek it with can be a daunting task, but breaking it down into the major elements that need to be considered will help you to develop an actionable plan.

WP-GettingReady-BP-Deal.jpg

Valuation of Your Early Drug Candidate 
Linda M. Pullan, Ph.D. Pullan Consulting

Biotech companies seek partnerships (collaborations, licensing deals, joint ventures, etc) to advance their drug candidates and raise funds. They frequently ask "How much is this drug candidate worth to a partner?" In this new white paper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Find out how valuation gets translated to deal terms and get a clear, conceptual framework for your drug's valuation.

 cover-valuation-sm.jpg

Building a Better Partnering Presentation
Linda M. Pullan, Ph.D., Pullan Consulting

To get a partnering deal done, you must persuade people you may never meet that your opportunity is the right one for them The partnering presentation, whether an elevator pitch, a one-pager, or a non-confidential deck, plays a key role in getting to a deal. In this webinar, Linda Pullan shares lessons she's learned over 20 years of doing in-licensing and out-licensing deals, with big companies and small companies.

 Building a Better Partnering Presentation

How to Win at the Partnering Game
Linda M. Pullan, Ph.D., Pullan Consulting 

An overview of biotech and pharmaceutical partnering with facts, fallacies, and tips. In this webinar, Linda Pullan provides a review of the rules of the partnering game - whether it's partnering from preclinical to late clinical development - to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisitions and how to win with a clear strategy.

 How to Win at the Partnering Game

Successful Biotech Licensing Negotiations
Linda M. Pullan, Ph.D., Pullan Consulting 

Biotech companies seeking to partner their drug candidates should decide in advance what they want to achieve in deal negotiations. Getting the best outcome depends on non-financial, as well as financial terms. In this webinar, Linda Pullan discusses negotiation goals, BATNAs and power, the process to the deal, the basics of term sheets, and common deal structures.

 Successful Biotech Licensing Negotiations

request the
linda pullan consulting series

 


 

ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.